早期肿瘤坏死因子拮抗剂治疗可预防儿童克罗恩病肛周瘘管发生:RISK研究的事后分析
RISK是多中心起始队列,纳入新诊断儿童克罗恩病且入组30天内无肛周瘘管并发症者,采用最近邻倾向性评分匹配三组分析。在447例匹配患者中,早期抗TNFα治疗与肛周瘘管并发症 odds 降低82%相关(OR 0.18,95%CI 0.05-0.66;p=0.01);伴有非穿透性肛周病变者中抗TNFα治疗与 odds 降低94%相关(OR 0.055,95%CI 0.006-0.50;p=0.010)。结论:早期抗TNF治疗可预防肛周瘘管发生,尤其在高风险患者中。
要点
- 非穿透性肛周病变(大皮赘、溃疡和/或肛裂)与肛周瘘管并发症发生显著相关(OR 4.08,95%CI 1.70-9.78;p=0.0016)。
- 早期抗TNFα治疗与肛周瘘管并发症 odds 降低82%相关(OR 0.18,95%CI 0.05-0.66;p=0.01)。
- 伴有肛周病变者中,抗TNFα治疗与肛周瘘管并发症 odds 降低94%相关(OR 0.055,95%CI 0.006-0.50;p=0.010)。
核心结论
- 早期抗TNF治疗可预防肛周瘘管发生,尤其在风险增加的患者中。
研究设计与样本
- RISK为多中心起始队列,纳入新诊断儿童克罗恩病且入组30天后从未发生肛周瘘管并发症的患者。
- 采用最近邻倾向性评分匹配三组分析,按肛周瘘管发生前或观察期结束前的治疗分为三个互斥治疗组进行匹配。
- 873例无肛周瘘管患者中纳入447例匹配患者,每组149例。
主要发现
- 非穿透性肛周病变(大皮赘、溃疡和/或肛裂)与肛周瘘管并发症发生显著相关,OR 4.08(95%CI 1.70-9.78;p=0.0016)。
- 早期抗TNFα治疗与肛周瘘管并发症 odds 降低82%相关(OR 0.18,95%CI 0.05-0.66;p=0.01)。
- 伴有肛周病变者中,抗TNFα治疗与肛周瘘管并发症 odds 降低94%相关(OR 0.055,95%CI 0.006-0.50;p=0.010)。
- 无其他治疗组与肛周瘘管并发症风险降低相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: One in three children with Crohn's disease develop perianal fistula complications (PFCs), among the most disturbing and difficult-to-treat disease-related complications. Retrospective evidence suggests PFCs may be preventable. OBJECTIVE: We aimed to determine if early antitumour necrosis factor-alpha (anti-TNF⍺) therapy prevents PFC development in a well-characterised prospective cohort of paediatric patients with Crohn's disease who were free from PFC at enrolment. DESIGN: RISK was a multicentre inception cohort of children newly diagnosed with Crohn's disease. We included all patients who had never experienced PFCs 30 days after study enrolment. We conducted nearest-neighbour propensity score-matched triad analyses. Matching was performed to balance patient characteristics across three mutually exclusive treatment groups based on therapy prior to either PFC development or the end of the observation period. RESULTS: Among 873 patients without perianal fistula, 447 matched patients were included (149 per treatment group). The presence of non-penetrating perianal lesions (large skin tags, ulcers and/or fissures) was significantly associated with PFC development, with 4-fold greater odds of PFC (OR 4.08, 95% CI (95% CI) 1.70 to 9.78; p=0.0016). Early anti-TNF⍺ therapy was associated with an 82% decrease in the odds of PFC (OR 0.18, 95% CI 0.05 to 0.66; p=0.01). Among those with perianal lesions, anti-TNF⍺ therapy was associated with 94% reduced odds of PFC development (OR 0.055, 95% CI 0.006 to 0.50; p=0.010). No other treatment group was associated with reduced risk of PFC. CONCLUSION: Early anti-TNF therapy prevents perianal fistula development, especially among patients at increased risk.
引用
- Adler J, Gadepalli S, Rahman M, et al. Early tumour necrosis factor antagonist treatment prevents perianal fistula development in children with Crohn's disease: post hoc analysis of the RISK study. Gut. 2025. PMID: 39667905. doi:10.1136/gutjnl-2024-333280
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。